Find Funding Opportunities

The National Institute of Neurological Disorders and Stroke (NINDS) announces the early termination of RFA-NS-21-016, HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed).

The NIH Blueprint for Neuroscience Research, with participating NIH Institutes and Centers (ICs), intends to promote the new Blueprint MedTech program by publishing a Funding Opportunity Announcement (FOA). The FOA is expected to be published in Summer 2021 with an expected application due date in Fall 2021. This FOA will utilize the U18 activity code. This FOA will support development of human-grade medical device prototypes. Leveraging resources from the BP MedTech program, projects will complete product definition and development (e.g., needs assessment, product design, prototype development, and bench testing). The end goal is to prepare for first-in-human testing via other FOAs within the BP MedTech program. Details of the planned program are provided below. This Notice is being provided for informational purposes to allow potential applicants additional time to develop responsive applications and meaningful collaborations. NIH reserves the right to modify the scope and objectives as described in this Notice. Final scope, objectives, and requirements will be set forth in the published FOAs.

The NIH Blueprint for Neuroscience Research, with participating NIH Institutes and Centers (ICs), intends to promote the new Blueprint MedTech program by publishing a Funding Opportunity Announcement (FOA). The FOA is expected to be published in summer 2021 with an expected application due date in fall 2021. This FOA will utilize the U44 activity code. Details of the planned program are provided below. This Notice is being provided for informational purposes to allow potential applicants additional time to develop responsive applications and meaningful collaborations. NIH reserves the right to modify the scope and objectives as described in this Notice. Final scope, objectives, and requirements will be set forth in the published FOAs

The NIH Blueprint for Neuroscience Research, with participating NIH Institutes and Centers (ICs), intends to promote the new Blueprint MedTech program by publishing a Funding Opportunity Announcement (FOA) to solicit applications to establish incubator hubs to provide medical device developers (innovators) with resources to support development of human-grade prototypes. The FOA intends to utilize the U54 activity code and is expected to be published in Summer 2021 with an expected application due date in Fall 2021. Incubator hubs will coordinate and manage resources for the Blueprint MedTech program, working as a consortium to provide: (1) infrastructure for identifying the most promising technologies, (2) the distribution of sub-award funding for innovators and resources to support product definition (e.g., needs assessment, product design, prototype development), and (3) access to relevant expertise (e.g., scientific, design, business development, and project management). Details of the planned program are provided below. This Notice is being provided for informational purposes to allow potential applicants additional time to develop responsive applications and meaningful collaborations. NIH reserves the right to modify the scope and objectives as described in this Notice. Final scope, objectives, and requirements will be set forth in the published FOAs.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.

This notice corrects the eligibility information for RFA-MH-21-180, "BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)" to clarify that NIH intramural candidates are eligible to apply.

The NINDS F32 is designed specifically to support postdoctoral fellows who are beginning their training period in a new laboratory or research environment. Applicants are only eligible to apply for the NINDS F32 either before beginning or within the first 12 months of joining the postdoctoral lab in which the fellowship will be active. Given this eligibility window, many applicants apply either before or within the first 3 months in the laboratory (~30% of applicants have been in the postdoctoral laboratory for less than 3 months). At the start of the COVID-19 pandemic many laboratories across the country shut down. This would have been particularly detrimental to those transitioning to their new positions, which in most cases required not only a change in research institution but a move to a different city and/or state. Clearly, for those starting a new postdoctoral position right as the pandemic hit, labs began to close down amid uncertainty and remote interactions were just beginning to be developed. Although pandemic-related delays were not unique to a specific cohort of trainees, the individuals who were just starting in new postdoctoral positions during the initial months of the pandemic were some of the hardest hit in terms of their ability to integrate into and begin research-related activities in new laboratories. Consequently, NINDS will provide a 1-receipt cycle extension of eligibility to individuals who started in their new laboratory between February 1 and May 30 of 2020. Ordinarily, the last NINDS F32 due date for these individuals would have been February, 2021. With this extension, these individuals will now be eligible to apply for the June, 2021 due date.

NOITP for RFA-MH-21-235 This Funding Opportunity Announcement (FOA) intends to support a group of large-scale Comprehensive Centers that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases of human and non-human primates with an emphasis on human. The Centers are expected to characterize all brain cell types (neurons, glia, and other non-neuronal cells) at high-resolution. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.

This is a time-sensitive Request for Information (RFI) to solicit input regarding revisions to the NIH Sleep Disorders Research Plan. It is issued by the National Heart, Lung, and Blood Institute (NHLBI), the National Center on Sleep Disorders Research (NCSDR), on behalf of the trans-NIH Sleep Research Coordinating Committee (SRCC).

NOITP for RFA-MH-21-236 This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases in human, non-human primates, and mouse, in coordination and collaboration with other BICAN projects. In particular, the Specialized Collaboratories are expected to complement the Comprehensive Centers in BICAN with distinct capabilities, competencies, and research aims. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.